понедельник, 19 сентября 2016 г.

How Risky Is Gilead Sciences Inc.?

How Risky Is Gilead Sciences Inc.?


Fears of incoming competition for the company's hepatitis C virus treatments have been exacerbated by declining sales among its HCV drug-based treatments. As a result, the stock is trading at a single-digit earnings multiple under the assumption it has reached a peak that it won't return to.



from Biotech News